What surprises might BSX's 2025 earnings hold?

**Boston Scientific's (BSX) 2025 earnings are poised to show robust growth**, based on the following points:

1. **Expected EPS and Revenue Growth**: Analysts anticipate that BSX will report earnings per share (EPS) of $0.67 for the upcoming quarter, reflecting a 19.64% increase from the same quarter of the previous year. Additionally, the projected revenue for the quarter is $4.56 billion, indicating an 18.2% year-over-year growth. For the full year, the Zacks Consensus Estimates suggest earnings of $2.85 per share and revenue of $19.05 billion, which would represent changes of +13.55% and +13.75%, respectively, from the prior year.

2. **Strong Financial Health and Resilience**: Despite broader economic disruptions, BSX is expected to show strong financial health, with a notable 17.61% revenue growth in the last twelve months. The company's focus on disposable medical products and its relative immunity to economic disruptions are key factors supporting its growth outlook.
3. **Positive Analyst Ratings and Target Price**: RBC Capital Markets has maintained an Outperform rating on BSX with a steady price target of $116.00, indicating confidence in the company's performance. The Zacks Rank, which considers estimate changes and provides a rating system, has placed BSX at #2 (Buy), suggesting potential for stock price appreciation.
4. **Strategic Catalysts and Market Opportunities**: BSX is actively working on strategic catalysts and exploring new market opportunities, such as Intravascular Lithotripsy (IVL), Renal Denervation (RDN), and additional indications for its Pulmonary Fibrosis Ablation (PFA) technology. These initiatives are expected to contribute significantly to the company's future growth.

In conclusion, BSX's 2025 earnings are likely to demonstrate substantial growth, driven by strong financial performance, strategic initiatives, and favorable market conditions.